Recent Articles from GlobeNewswire
Amsterdam 10 December 2025 | The Magnum Ice Cream Company (TMICC; AEX: “MICC”), the world’s largest ice cream company, today confirmed its inclusion in the AEX Index on Euronext Amsterdam as of its first day of trading on 8 December. The announcement follows Euronext’s quarterly index review, which is based on criteria, including free-float and market capitalisation.
By The Magnum Ice Cream Company N.V. · Via GlobeNewswire · December 10, 2025
Paris, France – December 10, 2025
By Viridien · Via GlobeNewswire · December 10, 2025
Strategic highlights:
By Aegon Ltd. · Via GlobeNewswire · December 10, 2025
Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk.
By Idorsia Pharmaceuticals Ltd · Via GlobeNewswire · December 10, 2025
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 11, 2025, subject to satisfaction of customary closing conditions.
By Denali Therapeutics Inc. · Via GlobeNewswire · December 10, 2025
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns.
By Terns Pharmaceuticals, Inc. · Via GlobeNewswire · December 9, 2025
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics.
By Structure Therapeutics Inc. · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 30, 2025 to file lead plaintiff applications in securities class action lawsuits against Synopsys, Inc. (“Synopsys” or the “Company”) (NasdaqGS: SNPS), if they purchased or otherwise acquired the Company’s securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”) and/or purchased or otherwise acquired Synopsys common stock in exchange for their shares of Ansys, Inc. (“Ansys”) common stock in the acquisition of Ansys. These actions are pending in the United States District Court for the Northern District of California
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK CITY and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE), if they purchased or otherwise acquired the Company’s securities between January 27, 2025 to October 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 23, 2025 to file lead plaintiff applications in a securities class action lawsuit against James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX), if they purchased or otherwise acquired the Company’s shares between May 20, 2025, and August 18, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Sprouts Farmers Market, Inc. (“Sprouts” or the “Company”) (NasdaqGS: SFM), if they purchased or otherwise acquired the Company’s securities between June 4, 2025 and October 29, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Arizona.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against DeFi Technologies Inc. (“DeFi” or the “Company”) (NasdaqCM: DEFT), if they purchased or otherwise acquired the Company’s securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against CarMax, Inc. (NYSE: KMX), if they purchased or otherwise acquired the Company’s securities between June 20, 2025 and November 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Maryland.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 12, 2026 to file lead plaintiff applications in a securities class action lawsuit against Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN), if they purchased or otherwise acquired the Company’s securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of Virginia.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 19, 2026 to file lead plaintiff applications in a securities class action lawsuit against Jayud Global Logistics Limited (“Jayud” or the “Company”) (NasdaqCM: JYD), if they purchased or otherwise acquired the Company’s securities between April 21, 2023 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Bitdeer Technologies Group (“Bitdeer” or the "Company") (NasdaqCM: BTDR), if they purchased or otherwise acquired the Company’s securities between June 6, 2024 and November 10, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
NEW YORK and NEW ORLEANS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Six Flags Entertainment Corporation f/k/a CopperSteel HoldCo, Inc. (NYSE: FUN), if they purchased or otherwise acquired the Company’s common stock pursuant or traceable to the company’s registration statement and prospectus issued in connection with the July 1, 2024 merger of legacy Six Flags Entertainment Corporation (“Legacy Six Flags”) with Cedar Fair, L.P. (“Cedar Fair”), and their subsidiaries and affiliates (the “Merger”). This action is pending in the United States District Court for the Northern District of Ohio.
By Kahn Swick & Foti, LLC · Via GlobeNewswire · December 9, 2025
LOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that it has launched the start of assembly production of the FX Super One MPV pre-production vehicles at the Company’s Hanford, CA factory in anticipation of the first pre-production vehicle off the line ceremony planned for December 21. This milestone also marks the near completion of the Bridge Closure for the Company’s Bridge strategy, covering a closed loop of supply chain, testing, logistics, customs clearance and production. This further validates the feasibility and strategic value of the Bridge model, across tariff adaptation, ICTS compliance, cost management, and operational efficiency.
By Faraday Future · Via GlobeNewswire · December 9, 2025
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
By Wave Life Sciences USA, Inc. · Via GlobeNewswire · December 9, 2025
WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $350.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about December 11, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,847,071 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
By Dyne Therapeutics, Inc. · Via GlobeNewswire · December 9, 2025
CHICAGO, IL, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Meshflow Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market (“Nasdaq”) and begin trading on December 10, 2025, under the ticker symbol “MESHU”. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “MESH” and “MESHW,” respectively. The offering is expected to close on December 11, 2025, subject to customary closing conditions.
By Meshflow Acquisition Corp · Via GlobeNewswire · December 9, 2025
BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share.
By Vera Therapeutics · Via GlobeNewswire · December 9, 2025
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of its novel BTK inhibitor orelabrutinib were presented at the 67th Annual Meeting of the American Society of Hematology (ASH).
By InnoCare Pharma · Via GlobeNewswire · December 9, 2025
The TEAM at Fiesta Productions is Bringing Its Unique MAGIC to the 2026 Rose Parade® and Sharing a Behind the Scenes Preview of the WOW Moments it Will Be Delivering!
By Fiesta Productions · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- (BUSINESSWIRE)—The law firm of Kirby McInerney LLP reminds Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) investors of the January 12, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Stride securities between October 22, 2025 through October 28, 2025 (“the Class Period”).
By Kirby McInerney LLP · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
LONG BEACH, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced it is expediting a dedicated Electron mission for the Korea Advanced Institute of Science and Technology (KAIST) and is scheduling the launch from Launch Complex 1 in less than 24 hours’ time.
By Rocket Lab Corporation · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio. The interview highlights the growing body of preclinical and clinical findings supporting the use of icovamenib in patients with diabetes.
By Biomea Fusion, Inc. · Via GlobeNewswire · December 9, 2025
DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced that it has entered into a sales agreement pursuant to which Strive may issue and sell shares of its Variable Rate Series A Perpetual Preferred Stock, $0.001 par value per share (the “SATA Stock”), having an aggregate offering price of up to $500,000,000 (the “ATM Program���).
By Strive, Inc. · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · December 9, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ALT5 (ALTS) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · December 9, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Gauzy (GAUZ) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Avantor, Inc. (“Avantor” or the “Company”) (NYSE:AVTR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
By Kirby McInerney LLP · Via GlobeNewswire · December 9, 2025
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
By Immix Biopharma, Inc. · Via GlobeNewswire · December 9, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Klarna (KLAR) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · December 9, 2025
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, announced Erik Wiik, President and Chief Executive Officer of KOIL Energy, and Kurt Keller, Chief Financial Officer of KOIL Energy, will present and host one-on-one meetings with investors at Sidoti’s Year-End Virtual Investor Conference, taking place on December 10-11, 2025.
By Koil Energy Solutions, Inc. · Via GlobeNewswire · December 9, 2025
POCAHONTAS, Ark., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tate, a global leader in innovative, sustainable, and customer-driven infrastructure solutions for mission-critical data center environments, has officially launched its new state-of-the-art manufacturing facility in Pocahontas, Arkansas. The new site expands Tate’s North American production footprint and strengthens its ability to deliver advanced, high-performance data center solutions at scale.
By Arkansas Economic Development Commission · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announces the retirement of Mr. William Casey McManemin from the Board of Managers of Dorchester Minerals Management GP LLC, the general partner of the Partnership’s general partner (the “Board”), effective December 31, 2025.
By Dorchester Minerals, L.P. · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 9, 2025
SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.
By Adaptive Biotechnologies · Via GlobeNewswire · December 9, 2025
TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce that it will host a live webinar on December 10, 2025 at 08:30 AM Eastern Time.
By Medicenna Therapeutics Corp. · Via GlobeNewswire · December 9, 2025
BEIJING, Dec. 10, 2025 (GLOBE NEWSWIRE) -- 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China, today announced its unaudited financial results for the third quarter of 2025.
By 17 Education & Technology Group Inc. · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- AlphaVest Acquisition Corp (NASDAQ: ATMV) (the “Company” or “AlphaVest”), a special purpose acquisition company, and AMC Corporation (“AMC”), a security and safety technology solutions company, today announced the completion of their previously announced business combination (“the Business Combination”).
By AMC Corporation · Via GlobeNewswire · December 9, 2025
ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan.
By Esperion Therapeutics, Inc. · Via GlobeNewswire · December 9, 2025
Amy Perry recognized on prestigious list for transformative leadership
By Banner Health · Via GlobeNewswire · December 9, 2025
MILWAUKEE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (NYSE: APAM) today reported that its preliminary assets under management ("AUM") as of November 30, 2025 totaled $180.8 billion. Artisan Funds and Artisan Global Funds accounted for $87.2 billion of total firm AUM, while separate accounts and other AUM1 accounted for $93.6 billion. During the fourth quarter of each year, certain Artisan Funds make their annual income and capital gains distributions. November month-end AUM includes the impact of approximately $800 million of Artisan Funds distributions that were not reinvested. Based on updated estimates, approximately $400 million of additional Artisan Funds distributions not reinvested are expected in December. Separately, the Firm had a $2.7 billion redemption in early December 2025 from a non-U.S. institutional client across three Growth team strategies, driven in part by local pension-market dynamics.
By Artisan Partners Asset Management Inc. · Via GlobeNewswire · December 9, 2025
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The board of directors of APA Corporation (Nasdaq: APA) has declared a regular cash dividend on the company's common shares.
By APA Corporation · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Apollo Commercial Real Estate Finance, Inc. (the “Company”) (NYSE:ARI) today announced the Board of Directors declared a dividend of $0.25 per share of common stock, which is payable on January 15, 2026 to common stockholders of record on December 31, 2025.
By Apollo Commercial Real Estate Finance, Inc. · Via GlobeNewswire · December 9, 2025
FREMONT, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX) (“Enovix”), a global high-performance battery company, today announced its participation in the following investor events:
By Enovix Corporation · Via GlobeNewswire · December 9, 2025
SAN JOSE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today announced that selling stockholders affiliated with Blackstone Inc. (the “Selling Stockholders”) intend to offer and sell 7,000,000 shares of Legence’s Class A common stock, par value $0.01 (“Common Stock”) in a secondary underwritten public offering. In connection with the offering, the Selling Stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of Common Stock on the same terms and conditions.
By Legence Corp · Via GlobeNewswire · December 9, 2025
MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025.
By BillionToOne, Inc. · Via GlobeNewswire · December 9, 2025
SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet’s Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company’s Series A common stock as determined based on the Black Scholes value on December 9, 2025, to be granted on December 9, 2025 to the three newly-hired employees.
By Sagimet Biosciences Inc. · Via GlobeNewswire · December 9, 2025
New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Ave Acquisition Corporation (the “Company”) (Nasdaq: HAVA), a blank check company, today announced that, commencing on December 15, 2025, holders of 14,500,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”), may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “HAVAU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “HAVA” and “HAVAR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, in order to separate the holders’ Units into Class A ordinary shares and rights.
By Harvard Ave Acquistion Corp · Via GlobeNewswire · December 9, 2025
By Michelin AIM FZCO · Via GlobeNewswire · December 9, 2025
Q3’26 Net Sales Increased 4% to $47.6 Million Led by 31% Increase in Fire Services Products, Representing 53% of Total Revenue
By Lakeland Industries, Inc. · Via GlobeNewswire · December 9, 2025
DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses is pleased to announce the promotion of Grant Eason to Managing Director.
By Capital Southwest Corporation · Via GlobeNewswire · December 9, 2025
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.
By Amneal Pharmaceuticals LLC · Via GlobeNewswire · December 9, 2025
Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · December 9, 2025
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Denali Therapeutics. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
By Denali Therapeutics Inc. · Via GlobeNewswire · December 9, 2025
MITCHEL FIELD, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the second quarter of its fiscal year 2026, ended October 31, 2025, on Thursday, December 11, 2025, at 4:30 PM Eastern Time.
By Frequency Electronics, Inc. · Via GlobeNewswire · December 9, 2025
SHANGHAI, CHINA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Able View Global Inc. (Nasdaq: ABLV) (“Able View” or the “Company”), one of the largest comprehensive brand management partners of international beauty and personal care brands in China, today announced that on December 4, 2025, the Company received a notification letter from the Nasdaq Listing Qualifications Department (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement from October 22, 2025 through December 3, 2025. As set forth in the Nasdaq Listing Rules 5550(a)(2) (“Nasdaq Listing Rule”), it requires that the closing bid price for the Company’s ordinary shares listed on the Nasdaq be maintained at a minimum of USD$1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency.
By Able View Global Inc. · Via GlobeNewswire · December 9, 2025
NAR forecasts existing-home sales to jump by 14% and home prices to rise by 4% in 2026
By National Association of Realtors® · Via GlobeNewswire · December 9, 2025
Potentially Market-Disruptive Advanced Technology Addresses Ethical Use of AI
By Cyber A.I. Group, Inc. · Via GlobeNewswire · December 9, 2025
DOVER, USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sunrise New Energy Co., Ltd. (“Sunrise”, the “Company”, “we” or “our”) (NASDAQ: EPOW) today announced the successful mid-term evaluation of a Guizhou Provincial Science and Technology Major Project it is undertaking. The project, titled "Key Technologies and Engineering of Novel Silicon-Carbon Anode Materials for Lithium-ion Batteries," has been awarded $730,000, which is allocated to advance the next-stage development of the silicon-carbon anode project.
By Sunrise New Energy Co., Ltd · Via GlobeNewswire · December 9, 2025
NEWPORT NEWS, Va., Dec. 09, 2025 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Newport News Shipbuilding (NNS) division hosted the keel laying ceremony today for Virginia-class attack submarine Barb (SSN 804).
By HII · Via GlobeNewswire · December 9, 2025
Deployment underscores Darktrace Federal’s momentum amid continued investment, team expansion, and demand for AI-powered cyber resilience
By Darktrace · Via GlobeNewswire · December 9, 2025
Palmetto Publishing Announces the Release of ALABAMA CANNIBALS
By Palmetto Publishing · Via GlobeNewswire · December 9, 2025
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.
By Spherix Global Insights · Via GlobeNewswire · December 9, 2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that the Fund’s Board of Directors has declared distributions on shares of the Fund’s 7.00% Series D Term Preferred Stock due 2029 (“Series D”), 6.000% Series J Term Preferred Stock due 2028 (“Series J”), 7.000% Series K Cumulative Preferred Stock (“Series K”), and 6.375% Series L Term Preferred Stock due 2029 (“Series L”).
By Priority Income Fund, Inc. · Via GlobeNewswire · December 9, 2025
Merrillville, Indiana, Dec. 09, 2025 (GLOBE NEWSWIRE) -- White Lodging, one of the hospitality industry’s leading hotel development, ownership, and management companies, is pleased to announce the promotion of David Cirincione to the role of Regional Director of Operations (RDO).
By White Lodging · Via GlobeNewswire · December 9, 2025
